Abstract

Biography

Ben Perry is currently Senior Discovery Manager at Drugs for Neglected Diseases initiative (DNDi), where he is responsible for Discovery Open Innovation.

At DNDi he has led the NTD Drug Discovery Booster since inception, and has been involved with the conception and implementation of several other initiatives focused on leishmaniasis and Chagas disease drug discovery at DNDi, including the Open Synthesis Network and the MycetOS projects.

Prior to joining DNDi, Ben spent 15 years in various medicinal chemistry roles at Celltech (UK), UCB (UK; Belgium), Addex Therapeutics (Switzerland) and Genkyotex (Switzerland). He has worked extensively in early-stage drug discovery across a variety of disease indications including oncology, autoimmune disorders, neurodegeneration and psychiatry.

His areas of research interest include the use of chemoinformatic and computational tools within medicinal chemistry, alternative research mechanisms, and the use of new technologies and research collaborations to further the drug discovery process. Ben holds a PhD in organic chemistry from Imperial College London and a MBA from IE Business School, Madrid.

Company profile

Register for BOS Basel 2022